Monteris Med Announces New Data From Clinical Studies Evaluating Laser Interstitial Thermal Therapy For Brain Lesions
LOS ANGELES, April 26, 2017 (GLOBE NEWSWIRE) -- Monteris Medical today announced new data were presented supporting the use of its NeuroBlate® System for brain lesions at the 2017 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The AANS scientific program, taking place from April 22-26, included presentations from three separate Monteris-sponsored studies.
Presenting on Monteris Medical’s LAISE study results, Andrew Sloan, M.D., F.A.C.S., Professor & Vice-Chair, Department of Neurosurgery and Director, Brain Tumor & Neuro-Oncology Center, University Hospitals Cleveland Medical Center, delivered an oral presentation titled “Laser Ablation in Stereotactic Neurosurgery (LAISE): A Multi-Institutional Retrospective Analysis of LITT for Glioma” which described the results of 97 patients whose lesions were ablated with the NeuroBlate System. Of the lesions analyzed, 48 percent were deep-seated, 57.8 percent were considered inoperable, and 1 percent were not suitable for chemotherapy. Also presented by Dr. Sloan and his co-investigators was a poster – recognized among 1,000 submissions with the Third Place Tumor e-Poster Award – titled “Laser Ablation in Stereotactic Neurosurgery (LAISE): A Multi-Institutional Retrospective Analysis of LITT for Brain Metastasis” describing results of 40 patients. These two presentations represent results from patients who had brain lesions ablated from 2011–2015 at nine US centers.
“LITT is a minimally invasive tool used to ablate soft tissue and lesions in the brain that have historically been challenging to access,” said Dr. Sloan. “These encouraging findings from the LAISE study offer preliminary evidence that NeuroBlate may be a viable solution in individuals whose tumors were previously considered inoperable.”
A separate prospective study, titled “Laser Ablation After Stereotactic Radiosurgery (LAASR) – Results of a Multi-Centered Prospective Study Stratified by Pathology,” examined the use of laser ablation on patients’ progressive brain lesions following prior stereotactic radiosurgery. Among 42 individuals receiving laser ablation between October 2012 and December 2015, 19 had biopsy-confirmed radiation necrosis, 20 had recurrent tumors and 3 had no biopsy.
“Approximately 15 percent of patients with brain metastases initially treated with stereotactic radiosurgery will have clinically significant tumor regrowth or radiation necrosis within 18 months, which can ultimately lead to neurological deterioration,” said Veronica L. Chiang, M.D., Associate Professor of Neurosurgery and of Therapeutic Radiology, Yale School of Medicine; Director of Stereotactic Radiosurgery and Medical Director, Gamma Knife Center at Yale New Haven Hospital. “The findings of the LAASR study suggest that LITT has utility on these types of lesions and should be considered for appropriate patients.”
Lastly, Dr. Clark Chen, Director of Stereotactic and Radiosurgery and Vice-Chairman of Academic Affairs at the University Of California San Diego Department Of Neurosurgery, presented two posters on data from Monteris Medical’s prospective multi-center registry (LAANTERN). The posters titled “Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN): Procedural Safety and Hospitalization” and “Clinical Utilization of Stereotactic Laser Ablation (SLA): an Analysis of the Multi-center Prospective Registry, LAANTERN” provide initial data on the first 50 patients enrolled in this ongoing study.
“The data presented at the AANS Annual Meeting supports NeuroBlate’s potential in addressing brain lesions that historically have not responded well to standard interventions,” said Daryle Petersen, Vice President of Clinical Affairs at Monteris Medical. “We are excited to present our first data extract from LAANTERN, our ongoing multi-center prospective registry on laser ablation. Open, frequent communications are vital to the success of any registry and we look forward to sharing results on this novel, minimally invasive technology at future meetings.”
About the NeuroBlate® System
The NeuroBlate System is indicated for use to ablate, necrotize or coagulate soft tissue encountered in the discipline of neurosurgery through the application of laser thermotherapy. NeuroBlate is a tool (as opposed to a “treatment”) and is not intended to treat any specific disease. Physicians should use their clinical judgment and experience when deciding whether to use NeuroBlate.
Monteris Medical’s LITT technology, including NeuroBlate and its predecessor AutoLITT, has been used in more than 1,250 patient procedures across 46 installed systems in the U.S. and Canada.
Full prescribing information for the NeuroBlate System is available at www.monteris.com.
About Monteris®
Monteris® Medical is a privately held company developing innovative MRI-guided, laser-based brain lesion therapy. Monteris Medical markets the NeuroBlate® System, a neurosurgical ablation device providing controlled therapy for brain lesions. The company also offers the Monteris Mini-Bolt, the only cranial bolt system that enables a robotic interface for protected and precise therapy delivery, as well as the AtamA™ Stabilization System for MRI-guided neurosurgical procedures requiring head fixation.
For more information on Monteris Medical please visit www.monteris.com.
Media Contacts: Erich Sandoval LAZAR PARTNERS LTD. for Monteris Medical esandoval@lazarpartners.com 917-497-2867